Nifty
:
10813.45
Sensex
:
36737.69
107.70 (1.01%)
408.68 (1.12%)
Nifty
Sensex
:
:
10813.45
36737.69
107.70 (1.01%)
408.68 (1.12%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
71/99

BSE: 500257 | NSE: LUPIN

NSE BSE
867.05
09-Jul-2020
  • Open
  • High
  • Low
  • Previous Close
  •  871.40
  •  882.00
  •  862.50
  •  865.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2106003
  •  18351.99
  •  956.00
  •  504.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 39,208.23
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 46,717.18
  • 0.58%
  • 3.13

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.92%
  • 0.71%
  • 10.69%
  • FII
  • DII
  • Others
  • 22.68%
  • 16.04%
  • 2.96%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.13
  • 5.54
  • -1.50

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.35
  • -4.45
  • -8.50

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -1.32
  • -24.16
  • -38.16

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.24
  • 26.04
  • 24.02

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.24
  • 4.25
  • 2.75

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.60
  • 15.36
  • 13.05

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
3,845.74
4,406.32
-12.72%
3,769.27
3,947.33
-4.51%
4,359.65
3,951.06
10.34%
4,418.38
3,855.93
14.59%
Expenses
3,320.42
3,534.03
-6.04%
3,340.17
3,265.72
2.28%
3,628.62
3,401.42
6.68%
3,558.16
3,328.96
6.89%
EBITDA
525.32
872.29
-39.78%
429.10
681.61
-37.05%
731.03
549.64
33.00%
860.22
526.97
63.24%
EBIDTM
13.66%
19.80%
11.38%
17.27%
16.77%
13.91%
19.47%
13.67%
Other Income
208.60
86.50
141.16%
93.59
40.20
132.81%
133.27
230.68
-42.23%
72.21
184.20
-60.80%
Interest
107.38
85.52
25.56%
88.60
78.46
12.92%
86.46
73.82
17.12%
85.62
68.72
24.59%
Depreciation
214.26
280.78
-23.69%
253.23
218.96
15.65%
321.47
265.49
21.09%
317.09
258.98
22.44%
PBT
495.37
594.73
-16.71%
-107.82
82.17
-
-90.11
441.01
-
529.72
383.47
38.14%
Tax
105.07
299.84
-64.96%
767.02
245.40
212.56%
34.30
172.91
-80.16%
227.98
181.14
25.86%
PAT
390.30
294.89
32.35%
-874.84
-163.23
-
-124.41
268.10
-
301.74
202.33
49.13%
PATM
10.15%
6.69%
-23.21%
-4.14%
-2.85%
6.79%
6.83%
5.25%
EPS
8.62
6.51
32.41%
-19.31
-3.60
-
-2.75
5.92
-
6.66
4.47
48.99%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
16,393.04
16,718.18
15,804.15
17,494.33
14,255.54
12,770.01
11,286.57
9,641.30
7,082.91
5,818.97
4,870.79
Net Sales Growth
1.44%
5.78%
-9.66%
22.72%
11.63%
13.14%
17.06%
36.12%
21.72%
19.47%
 
Cost Of Goods Sold
5,841.62
5,234.59
4,733.76
4,660.97
4,010.21
3,806.16
3,485.50
3,221.50
2,364.87
2,060.99
1,821.29
Gross Profit
10,551.42
11,483.59
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
3,757.98
3,049.50
GP Margin
64.37%
68.69%
70.05%
73.36%
71.87%
70.19%
69.12%
66.59%
66.61%
64.58%
62.61%
Total Expenditure
13,847.37
13,835.96
12,656.64
13,001.19
10,570.19
9,150.42
8,283.78
7,371.41
5,638.20
4,641.13
3,886.90
Power & Fuel Cost
-
475.51
433.88
377.86
381.27
362.81
334.29
320.22
268.82
205.47
154.66
% Of Sales
-
2.84%
2.75%
2.16%
2.67%
2.84%
2.96%
3.32%
3.80%
3.53%
3.18%
Employee Cost
-
3,151.29
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
767.56
549.96
% Of Sales
-
18.85%
18.13%
16.29%
15.02%
13.68%
12.98%
13.14%
13.69%
13.19%
11.29%
Manufacturing Exp.
-
2,030.42
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
603.68
500.14
% Of Sales
-
12.14%
13.21%
12.98%
12.39%
10.34%
10.01%
10.13%
10.63%
10.37%
10.27%
General & Admin Exp.
-
1,429.32
1,219.96
1,306.27
1,195.98
806.87
810.53
692.06
471.23
325.19
292.37
% Of Sales
-
8.55%
7.72%
7.47%
8.39%
6.32%
7.18%
7.18%
6.65%
5.59%
6.00%
Selling & Distn. Exp.
-
1,298.77
1,150.61
1,252.77
870.29
835.48
775.26
709.62
647.88
547.48
446.97
% Of Sales
-
7.77%
7.28%
7.16%
6.10%
6.54%
6.87%
7.36%
9.15%
9.41%
9.18%
Miscellaneous Exp.
-
216.06
166.20
283.61
204.82
271.21
283.96
184.88
162.80
130.76
446.97
% Of Sales
-
1.29%
1.05%
1.62%
1.44%
2.12%
2.52%
1.92%
2.30%
2.25%
2.49%
EBITDA
2,545.67
2,882.22
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
1,177.84
983.89
EBITDA Margin
15.53%
17.24%
19.92%
25.68%
25.85%
28.34%
26.60%
23.54%
20.40%
20.24%
20.20%
Other Income
507.67
364.02
150.35
106.51
185.19
239.75
116.48
27.85
14.35
22.19
14.20
Interest
368.06
307.83
204.35
152.53
59.47
9.81
26.65
40.95
35.47
34.48
38.49
Depreciation
1,106.05
1,085.01
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
171.18
123.91
PBT
827.16
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
Tax
1,134.37
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
114.98
136.02
Tax Rate
137.14%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
11.56%
16.28%
PAT
-307.21
602.80
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
864.55
688.51
PAT before Minority Interest
-303.19
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
879.39
699.67
Minority Interest
4.02
-8.93
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
-14.84
-11.16
PAT Margin
-1.87%
3.61%
1.57%
14.57%
15.82%
18.82%
16.27%
13.63%
12.25%
14.86%
14.14%
PAT Growth
-151.02%
143.32%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
0.36%
25.57%
 
EPS
-6.78
13.31
5.47
56.27
49.80
53.05
40.54
29.01
19.15
19.08
15.20

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
3,281.08
2,567.83
Share Capital
90.50
90.42
90.32
90.12
89.90
89.68
89.51
89.33
89.24
88.94
Total Reserves
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
3,190.59
2,478.35
Non-Current Liabilities
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
533.59
1,283.35
Secured Loans
358.82
448.03
217.15
5.55
12.50
24.42
37.95
27.76
54.25
872.24
Unsecured Loans
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
244.91
267.61
Long Term Provisions
370.79
356.85
308.73
190.00
162.03
132.49
112.45
77.02
37.28
0.00
Current Liabilities
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
2,507.37
1,189.25
Trade Payables
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
993.03
883.52
Other Current Liabilities
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
201.02
82.82
Short Term Borrowings
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
791.09
0.00
Short Term Provisions
771.66
551.23
569.39
325.67
574.26
345.40
355.97
316.86
522.23
222.91
Total Liabilities
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92
Net Block
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
2,056.83
1,906.17
Gross Block
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
2,964.34
2,613.39
Accumulated Depreciation
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
907.51
707.22
Non Current Assets
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
2,869.33
2,290.47
Capital Work in Progress
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
478.17
348.80
Non Current Investment
185.63
26.71
22.00
14.33
2.51
2.06
2.06
2.80
3.15
26.43
Long Term Loans & Adv.
402.61
383.00
950.76
960.22
274.20
372.99
387.36
396.94
314.42
0.00
Other Non Current Assets
47.13
9.38
7.96
7.70
0.32
0.00
0.00
0.00
4.52
0.00
Current Assets
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
3,504.22
2,775.45
Current Investments
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
0.00
0.00
Inventories
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
1,199.96
971.49
Sundry Debtors
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
1,255.64
1,126.57
Cash & Bank
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
420.14
201.53
Other Current Assets
1,769.95
621.30
533.43
479.44
534.98
532.99
572.33
427.17
628.48
475.86
Short Term Loans & Adv.
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
515.64
475.86
Net Current Assets
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
996.85
1,586.20
Total Assets
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
797.98
676.41
PBT
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
Adjustment
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
207.16
144.33
Changes in Working Capital
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
-159.56
-136.62
Cash after chg. in Working capital
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
1,041.97
843.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
-243.99
-166.99
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
-519.56
-680.17
Net Fixed Assets
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
-558.11
-309.75
Net Investments
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
43.19
-250.20
Others
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
-4.64
-120.22
Cash from Financing Activity
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
-162.52
136.13
Net Cash Inflow / Outflow
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
115.90
132.37
Opening Cash & Equivalents
1,416.43
687.47
780.22
2,095.06
606.62
310.93
244.65
295.88
164.22
68.08
Closing Cash & Equivalent
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62
310.93
244.65
295.88
197.99

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
298.87
295.64
295.04
245.21
196.17
154.00
116.13
89.78
73.51
57.73
ROA
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
15.37%
15.44%
ROE
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
30.08%
35.05%
ROCE
8.48%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
25.24%
27.51%
Fixed Asset Turnover
1.95
2.07
1.62
1.80
2.15
2.28
2.19
1.99
2.10
2.06
Receivable days
65.46
63.76
92.39
92.24
72.65
74.67
74.61
77.76
74.26
76.18
Inventory Days
47.47
49.03
72.15
73.96
65.73
65.48
69.24
75.12
67.69
71.86
Payable days
59.26
68.56
59.62
63.20
64.43
63.78
63.76
64.11
61.46
64.47
Cash Conversion Cycle
53.67
44.23
104.91
103.00
73.94
76.37
80.10
88.76
80.49
83.57
Total Debt/Equity
0.63
0.53
0.60
0.65
0.06
0.09
0.22
0.41
0.35
0.44
Interest Cover
5.92
3.66
24.18
56.89
349.10
107.25
48.00
34.72
29.84
22.71

Annual Reports:

FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011
FY 2010

News Update:


  • Lupin recalls all batches of Metformin Hydrochloride extended-release tablets in US
    8th Jul 2020, 10:14 AM

    This recall is being conducted out of an abundance of caution in line with the ongoing interaction with the U.S. Food and Drug Administration on NDMA impurity levels

    Read More
  • Lupin planning to approach USFDA for re-inspection of key plants
    15th Jun 2020, 11:26 AM

    The Somerset (New Jersey) plant is currently under the official action indicated status

    Read More
  • Lupin gets USFDA’s nod for Albendazole Tablets
    12th Jun 2020, 10:07 AM

    Albendazole Tablets USP had an annual sales of approximately $34 million in the U.S.

    Read More
  • USFDA grants mexiletine orphan drug designation to Lupin
    8th Jun 2020, 11:28 AM

    The company has received the designation to mexiletine hydrochloride for the treatment of myotonic disorders

    Read More
  • Lupin, Mylan receive European Marketing Authorization for Nepexto, Biosimilar Etanercept
    5th Jun 2020, 09:56 AM

    The regulatory approval follows the adoption of a positive opinion by the Committee for Medicinal Products for Human Use in March this year

    Read More
  • Lupin signs distribution agreement in key EU territories for orphan drug NaMuscla
    3rd Jun 2020, 11:18 AM

    NaMuscla will commercialize for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders in certain EU territories

    Read More
  • Lupin receives USFDA’s approval for Meloxicam Capsules
    3rd Jun 2020, 09:33 AM

    The product would be manufactured at company’s Aurangabad facility, India, and is expected to be launched shortly

    Read More
  • Lupin gets USFDA’s nod for Trientine Hydrochloride Capsules USP
    22nd May 2020, 13:19 PM

    Trientine Hydrochloride Capsules USP, 250 mg, are indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine

    Read More
  • Lupin launches authorized generic version of Apriso
    19th May 2020, 13:26 PM

    Mesalamine Extended-Release Capsules 0.375 g, RLD Apriso had an annual sales of approximately $290 million in the U.S.

    Read More
  • Lupin receives EIR from USFDA for Vizag API Facility
    14th May 2020, 10:26 AM

    The inspection for the API facility was conducted by the USFDA between January 13, 2020 and January 17, 2020

    Read More
  • UK MHRA completes inspection at Lupin’s Pithampur facilities
    9th May 2020, 09:38 AM

    The inspection for the three units at Pithampur was conducted in January 2020

    Read More
  • Lupin launches ‘Jan Kovid’ Helpline for Mumbai Citizens
    6th May 2020, 13:18 PM

    This initiative facilitates medical outreach to citizens to resolve queries about COVID-19

    Read More
  • Lupin’s arm declares positive topline results from Phase 3 Study of Single-Dose Solosec
    5th May 2020, 11:03 AM

    Based on the data, the company plans to submit a supplemental New Drug Application to the USFDA for Solosec for the treatment of trichomoniasis

    Read More
  • Lupin receives EIR from USFDA for Pithampur Unit-1 facility
    30th Apr 2020, 10:35 AM

    The inspection for the facility was conducted by the USFDA between February 3, 2020 and February 11, 2020

    Read More
  • Lupin gets USFDA’s tentative approval for Arformoterol Tartrate Inhalation Solution
    29th Apr 2020, 13:53 PM

    Arformoterol Tartrate Inhalation Solution are indicated for the long-term maintenance treatment of bronchoconstriction in patients with COPD

    Read More
  • Lupin receives EIR from USFDA for Mandideep Unit II facility
    15th Apr 2020, 10:27 AM

    The inspection at the facility was carried out by the USFDA between November 26, 2018 and December 4, 2018

    Read More
  • Lupin receives EIR from USFDA for Nagpur Facility
    13th Apr 2020, 11:06 AM

    The inspection for the facility was carried out by the USFDA between January 6, 2020 and January 10, 2020

    Read More
  • Lupin launches Mycophenolic Acid Delayed-Release Tablets USP
    6th Apr 2020, 12:00 PM

    The company’s alliance partner Concord Biotech had received an approval from the USFDA earlier

    Read More
  • Lupin's Aurangabad Facility Receives EIR from USFDA
    3rd Apr 2020, 10:47 AM

    The inspection for the facility was carried out by the USFDA between February 10, 2020 and February 14, 2020

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.